Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

Gang Shen; Lei Shi; Xin Tian; Depei Huang; Hao Chen; Chan Gao; Xudong Shen; Hushan Zhang

doi:10.3389/fphar.2021.731895

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

Front Pharmacol. 2021 Dec 20:12:731895. doi: 10.3389/fphar.2021.731895. eCollection 2021.

Authors

Gang Shen¹, Lei Shi¹, Xin Tian², Depei Huang³, Hao Chen⁴, Chan Gao³, Xudong Shen³, Hushan Zhang³

Affiliations

¹ Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
³ The Medical Department, 3D Medicines Inc., Shanghai, China.
⁴ The Bioinformatics Department, 3D Medicines Inc., Shanghai, China.

Abstract

Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.

Keywords: EGFR; L718Q; NSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1.; TKI-tyrosine kinase inhibitor; almonertinib.

Publication types

Case Reports